Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes
Conditions
Brief summary
In this study, four new tablet versions of two compounds will be investigated. The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood after doses of four different tablet versions. The tablet versions, participants will receive, i.e. the treatment arm participants will be assigned to, is decided by chance. Participants will receive one treatment for 10 days in the first period. For the second period, directly following, participants will receive a different treatment for five more days. The study can last for up to approximately 10 weeks for each participant. This includes a screening period (up to 3 weeks), two treatment periods (together a total of 15 days) and a follow-up visit (5 weeks after the last dosing)
Interventions
DRUGSemaglutide D
Tablet given orally
DRUGSemaglutide G
Tablet given orally
DRUGSemaglutide H
Tablet given orally
DRUGSemaglutide I
Tablet given orally
DRUGNNC0385-0434 B
Tablet given orally
DRUGNNC0385-0434 C
Tablet given orally
DRUGNNC0385-0434 D
Tablet given orally
DRUGNNC0385-0434 E
Tablet given orally
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male. * Aged 18-55 years (both inclusive) at the time of signing informed consent. * Body mass index between 20.0 and 29.9 kg/m\^2 (both inclusive). * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion criteria
* Known or suspected hypersensitivity to study interventions or related products. * Use of prescription medicinal products or non-prescription drugs (including herbal products and vaccines), except routine vitamins and topical medications not reaching the systemic circulation, within 14 days prior to the day of screening. * Any disorder which in the investigator's opinion might jeopardise participant safety or compliance with the protocol. * Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator. * History (as declared by the participant or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of study products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose | From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration | h \* nmol/L |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax,API,day10; maximum observed plasma concentration of API after the 10th dose | From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration | nmol/L |
| tmax, API,day10; time from the 10th dose to maximal observed plasma concentration of API | From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration | hours |
Countries
Canada, Germany
Outcome results
None listed